Preliminary phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Beslija, S.
Banjin, M.
Jungic, S.
Obralic, N.
Kecman-Malcic, G.
Rakita, I.
Salkic, B.
Pasic, A.
Tinjic, L.
Ajanovic, E.
机构：
[1] Inst Oncol, Sarajevo, Bosnia & Herceg
[2] Inst Oncol, Banja Luka, Bosnia & Herceg
[3] Hoffmann La Roche, Sarajevo, Bosnia & Herceg
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14502
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [2] Updated phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [4] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 76 - 76
  • [5] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [6] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [7] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [8] A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (1) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Perez-Manga, G
    Gonzalez, MC
    Lopez, P
    Gonzalez, E
    Belon, J
    Molina, M
    Pachon, V
    Iglesias, L
    Siso, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 256S - 256S
  • [9] A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (PTS) with advanced or metastatic colorectal cancer (MCRC)
    Maroun, Jean A.
    Jonker, Derek
    Goel, Rakesh
    Cripps, Christine
    Lister, Diane
    Chiritescu, Gabriela
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [10] Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
    Doi, Toshihiko
    Boku, Narikazu
    Kato, Ken
    Komatsu, Yoshito
    Yamaguchi, Kensei
    Muro, Kei
    Hamamoto, Yasuo
    Sato, Atsushi
    Koizumi, Wasaburo
    Mizunuma, Nobuyuki
    Takiuchi, Hiroya
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 913 - 920
12345